Mallinckrodt’s liver disease drug terlipressin edges FDA adv...

An FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type 1 (HRS-1), after the agency questioned the findi

COVID-19 and vulnerable children: Urging caution while enjoy...

How do you keep a child with a suppressed immune system safe during COVID-19 lockdown? And how do you explain the dangers while protecting their – and your own – mental health?

Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems with long waiting lists for kidney and liver transplants

Conatus axes staff after latest failure of Novartis-partnere...

Gilead NASH drug fails late stage trial

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.

Promethera looks to Asia with €10m investment

Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of a €10 million investment from Japanese business conglomerate ITOCHU Corp